Biology Insights

Are Uterine Polyps Common and When Are They a Concern?

Are uterine polyps common? Understand the prevalence, signs, diagnosis, and the rare concerns for malignancy.

By Ying Yang

Uterine polyps, also called endometrial polyps, are among the most frequently encountered findings in gynecologic imaging. They affect women across a wide age range, from their twenties through well past menopause, and the vast majority turn out to be benign. Still, the discovery of a polyp raises immediate questions about whether it needs to come out, whether it could be cancerous, and whether it might be affecting fertility. The answers depend heavily on individual factors like age, symptoms, and menopausal status.

How Common Are They

Reported prevalence varies dramatically depending on who is being studied and how they are screened. In a population-based study of Danish women aged 20 to 74, the overall prevalence of endometrial polyps was about 8%, rising from under 1% in women younger than 30 to roughly 12% in postmenopausal women. When researchers look specifically at women undergoing evaluation for symptoms or fertility, the numbers jump much higher. One review pegged the prevalence at around 40% among women diagnosed during workups, though most of those polyps were found incidentally. The gap between those numbers reflects a simple reality: many polyps never cause symptoms, so you only find them if you look. In the Danish study, a full 82% of women with confirmed polyps had no symptoms at all.

The increased use of pelvic ultrasound over the past two decades has made incidental polyp detection far more common, which in turn has created a growing clinical dilemma: what to do when a polyp shows up on imaging in a woman who feels perfectly fine.

Why They Form

Endometrial polyps are overgrowths of the glands and supporting tissue that make up the uterine lining. They typically protrude into the uterine cavity, sometimes on a thin stalk (pedunculated) and sometimes on a broad base (sessile). They can range from a few millimeters to several centimeters across.

The leading theory for why polyps develop centers on estrogen. The glandular tissue inside polyps has higher concentrations of estrogen receptors compared with the surrounding normal lining, which means the polyp tissue responds more aggressively to estrogen stimulation and grows disproportionately. Research in postmenopausal women has confirmed that estrogen receptors play a particularly outsized role in driving polyp growth in that population. This estrogen sensitivity helps explain many of the known risk factors.

Who Is Most at Risk

Age is the single strongest independent predictor. When researchers controlled for other variables like obesity, high blood pressure, and diabetes, age was the only factor that remained statistically significant on its own. That said, other conditions frequently show up alongside polyps even if the causal link is less clean. Conditions associated with higher estrogen exposure, including obesity and hormone replacement therapy, are commonly mentioned in the literature, along with hypertension and diabetes.

The one medication with the most clearly established polyp risk is tamoxifen, a drug widely used in breast cancer treatment. Tamoxifen acts as an estrogen blocker in breast tissue but has estrogen-like effects on the uterine lining. Women taking tamoxifen develop polyps at rates of roughly 8 to 36%, compared with 0 to 10% in untreated women. In premenopausal tamoxifen users, the incidence of newly diagnosed polyps has been measured at about 20 cases per 1,000 person-years. The polyps that form in tamoxifen users tend to be larger, averaging around 5 cm compared with a typical 0.5 to 3 cm, and they have unusual microscopic features that can make them harder to remove. Duration of tamoxifen use and number of prior pregnancies have both been linked to polyp development in these patients.

When to Worry About Cancer

The question most women want answered is whether a polyp could be cancerous. The short version: it is uncommon, but it happens, and the risk is not evenly distributed. A large meta-analysis pooling data from more than 35,000 women found that about 2.7% of endometrial polyps harbored malignancy. A separate meta-analysis of about 21,000 patients put the combined rate of premalignant and malignant findings at roughly 3.4%. Either way, the vast majority of polyps are benign. In one institutional series of about 1,000 polyps, more than 95% were benign on pathology review.

What shifts the risk meaningfully is a combination of factors:

The practical takeaway: a small polyp found incidentally in a premenopausal woman with no symptoms sits at the low end of concern. A large polyp causing bleeding in a postmenopausal woman warrants prompt removal and pathology review.

How They Are Diagnosed

Most polyps are first spotted on a standard transvaginal ultrasound, often during a routine exam or a workup for abnormal bleeding. Ultrasound is a reasonable first step but has limitations. A meta-analysis comparing diagnostic methods found that transvaginal ultrasound caught about 62% of polyps (sensitivity) and correctly ruled them out about 73% of the time (specificity). That means ultrasound misses a meaningful fraction of polyps, particularly smaller ones. One study did find ultrasound performed just as well as hysteroscopy when evaluating infertile women, so the accuracy can vary with patient population and imaging quality.

Saline infusion sonohysterography, where sterile saline is injected into the uterine cavity before ultrasound, improves accuracy considerably. The same meta-analysis found this approach reached about 87% sensitivity and 86% specificity. The fluid fills the cavity and outlines the polyp, making it much easier to see.

Hysteroscopy, where a thin camera is threaded through the cervix to view the cavity directly, is considered the gold standard for visualization. It reached about 92% sensitivity in the same analysis. Its real advantage is that it allows the doctor to see the polyp directly and, in many cases, remove it during the same procedure. A separate comparison confirmed hysteroscopy’s edge for detecting polyps of any size, though for polyps larger than 1 cm, ultrasound performed comparably. Final diagnosis always depends on sending the removed tissue to a pathologist, since no imaging method can definitively rule out cancer.

Do Some Polyps Disappear on Their Own

This is one of the more genuinely useful things to know, especially if you have been told to “watch and wait.” Some polyps do spontaneously regress, but the rates vary by study. In one prospective series, about 23% of polyps had disappeared by the time of a follow-up hysteroscopy. Regression was more likely in women under 45, in those who were premenopausal, and when the polyp was smaller than 2 cm. Every postmenopausal woman in that study still had her polyp at follow-up. A different study tracking polyps over a median of about two and a half years found a lower spontaneous regression rate, around 6%. The discrepancy likely reflects differences in follow-up length and patient populations, but both studies agree that regression is more common in younger, premenopausal women with smaller polyps.

This means watchful waiting can be a reasonable strategy for a young, asymptomatic woman with a small polyp. For postmenopausal women or anyone with symptoms, passive monitoring is less appealing because the polyp is unlikely to resolve and the stakes are higher.

How Polyps Affect Fertility

The link between endometrial polyps and difficulty conceiving has been studied extensively, though the evidence is still evolving. Several mechanisms have been proposed, including physical blockage of sperm transport or embryo implantation, chronic low-grade inflammation within the uterine cavity, and molecular changes in the endometrial lining that make it less hospitable to an embryo.

On the molecular side, research has found that the presence of a polyp reduces the expression of genes critical for implantation throughout the entire uterine lining, not just at the polyp site. Expression of two key genes involved in making the lining receptive to embryos was significantly decreased in uteri containing polyps compared with controls. This suggests that even a single polyp can alter the chemical environment of the whole uterine cavity.

The encouraging news is that removing polyps appears to help. In a study of infertile women who underwent hysteroscopic polypectomy, roughly 61% achieved spontaneous pregnancy afterward, and about 54% delivered at term. Despite these positive outcomes, there is still no firm consensus on exactly which polyps in which patients must come out before fertility treatment, and recommendations can vary between clinicians.

Treatment Options

When removal is warranted, the standard approach is hysteroscopic polypectomy, a minimally invasive outpatient procedure done through the cervix under direct visualization. No abdominal incisions are involved. The two main techniques are resectoscopy, which uses an electrified loop to cut and cauterize, and hysteroscopic morcellation, which uses a rotating blade to shave and suction the tissue.

Head-to-head comparisons show the two approaches have essentially the same success rate, but morcellation tends to be faster. One randomized trial found operating time was reduced by about 38% with morcellation compared with resectoscopy. A meta-analysis confirmed similar success rates between the two, with morcellation shaving a few minutes off procedure time and no meaningful difference in complications like fluid absorption. Both are considered safe, though perforation of the uterus is a rare complication. In the randomized trial, perforation occurred in three patients in the resectoscopy group and one in the morcellation group. For most patients, recovery is quick and the procedure is well tolerated.

Recurrence and Prevention

One frustrating reality of polyps is that they tend to come back. How often depends on follow-up duration and the population studied. One study tracking women after hysteroscopic polypectomy found that 43% developed recurrent polyps, with the number of original polyps and the length of follow-up being the strongest predictors of recurrence. Another study of reproductive-age women found a lower recurrence rate of 8%, with a median time to recurrence of about three and a half years. That study identified adenomyosis, polycystic ovarian syndrome, obesity, tamoxifen use, and fibroids as significant risk factors for coming back. The choice of surgical instrument may also matter: one trial found a recurrence rate of 6% with a tissue-removal device compared with about 15% with a traditional cold knife approach.

The most promising prevention strategy identified so far is the levonorgestrel-releasing intrauterine system, commonly known by brand names like Mirena. This device releases a small amount of progestin directly into the uterine cavity, which thins the lining and counteracts the estrogen-driven growth that gives rise to polyps. A retrospective study found a recurrence rate of about 3.5% in women who received the device after polypectomy, versus 16% in women who did not, over a three-year follow-up. There is also evidence that the same device can cause existing polyps to shrink. A pilot study demonstrated polyp regression confirmed by direct hysteroscopic visualization in women with heavy menstrual bleeding who were treated with the device. The large recurrence-risk study also confirmed the protective effect, finding that the device slashed recurrence odds dramatically. For women who have had polyps removed and are not trying to conceive, this device serves double duty as contraception and polyp prevention.

The Emerging Genetics of Polyps

One of the more interesting areas of recent research is what is happening inside polyps at the genetic level. Far from being random lumps, endometrial polyps carry recurrent genetic alterations that resemble those seen in other benign tumors. A 2025 genomic analysis found that about three-quarters of polyps studied had chromosomal rearrangements affecting two specific genes, HMGA1 and HMGA2, which drive tissue overgrowth. The same study also identified mutations in well-known cancer-related genes like KRAS, PIK3CA, and PTEN, though these were present at low levels. Earlier work had already shown that nearly half of polyps harbor mutations in RAS-family genes, and that women whose polyps carried these mutations tended to have more polyps. Chromosome rearrangements at specific regions had been recognized in polyps as far back as the 1990s.

None of this currently changes clinical management. No one is genotyping polyps to decide whether to remove them. But the research is filling in a picture of polyps as clonal growths driven by specific molecular events, not just passive responses to estrogen. Over time, understanding these pathways could help explain why some polyps recur stubbornly, why some progress to malignancy, and potentially open the door to targeted medical treatments that go beyond surgery.

Related Content

More in Reproductive